Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492256 | 1.00 | PDK1 (0.54) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL7493594 | 1.00 | PDK1 (0.54) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL21081162 | 0.95 | PARP1 (0.57) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL2442588 | 0.92 | PDK1 (0.55) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL933923 | 0.92 | PDK1 (0.55) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL375852 | 0.92 | PDK1 (0.55) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL4676650 | 0.91 | PDK1 (0.54) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL3779343 | 0.91 | PDK1 (0.54) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL30289331 | 0.91 | PDK1 (0.54) | PDK1PDK2PDK3PDK4PARP1 | |
| SCHEMBL20299772 | 0.90 | PDK1 (0.53) | PDK1PDK2PDK3PDK4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | PDK1 269/4885PDK2 1166/4885PDK3 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.